Autopsy report · NCT02994251
A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
Cause of deathSlow enrollment, also futility
“Study terminated due to low enrollment making it unlikely to meet recruitment goals.”
Life of this trial
- Registered 6 months before it started.
- Ran for about 1 year 5 months before it stopped.
- 1 participant enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Conditions
- Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- gemcitabine; Cisplatin; Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
- Participants
- 1
- Sites
- 1
- Countries
- United States
Trials that died the same way
- HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
“The clinical study was terminated due to the inability to meet target enrollment.” - Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
“Study terminated due to low enrollment.” - BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
“Study was terminated due to low enrollment.” - Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
“Study terminated prematurely due to poor recruitment.” - Improving Surgical Safety of Seniors Through Preoperative Cognitive Screening
“This study was terminated prior to its planned enrollment due to low recruitment rates at the time that the funding for the study was completed.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.